| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ECSIT |
| Uniprot No | E9PAN9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-217aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSGTCGAALTGTSISQVPLPKDSTGAADP PQPHIVGIQSPDQQAALARHNPARPVFVEGPFSLWLRNKCVYYHILRADL LPPEEREVEETPEEWNLYYPMQLDLEYVRSGWDNYEFDINEVEEGPVFAM CMAGAHDQATMAKWIQGLQETNPTLAQIPVVFRLAGSTRELQTSSAGLEE PPLPEDHQEEDDNLQRQQQGQS |
| 预测分子量 | 25 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ECSIT重组蛋白的参考文献及摘要概览：
---
1. **文献名称**: *"ECSIT is an evolutionarily conserved intermediate in the Toll/IL-1 signal transduction pathway"*
**作者**: Kopp, E. et al.
**摘要**: 本研究首次报道了ECSIT作为Toll样受体(TLR)和IL-1信号通路的关键衔接蛋白，通过重组蛋白技术验证了其与TRAF6的相互作用，并证明其参与NF-κB的激活，揭示了其在先天免疫中的调控作用。
2. **文献名称**: *"Regulation of mitochondrial complex III assembly by ECSIT"*
**作者**: West, A.P. et al.
**摘要**: 文章利用重组ECSIT蛋白进行功能分析，发现其不仅参与TLR信号通路，还通过与线粒体复合物III亚基的相互作用调控氧化磷酸化，揭示了ECSIT在能量代谢和炎症反应中的双重功能。
3. **文献名称**: *"Recombinant ECSIT protein enhances BMP signaling through direct interaction with Smad1"*
**作者**: Matsuda, A. et al.
**摘要**: 研究通过表达纯化重组ECSIT蛋白，发现其能够直接结合Smad1.促进BMP(骨形态发生蛋白)信号通路的转导，为理解ECSIT在胚胎发育和组织稳态中的作用提供了新机制。
4. **文献名称**: *"Structural and functional analysis of ECSIT in VEGF-mediated angiogenesis"*
**作者**: Sánchez-Cabo, F. et al.
**摘要**: 该研究解析了重组ECSIT蛋白的结构，并证明其在血管内皮生长因子(VEGF)信号中通过调控ROS生成促进血管生成，为靶向ECSIT的癌症治疗提供了理论基础。
---
以上文献涵盖了ECSIT在免疫信号、线粒体功能、发育调控及疾病机制中的多重角色，均通过重组蛋白技术验证其分子机制。
ECSIT (Evolutionarily Conserved Signaling Intermediate in Toll pathways) is a multifunctional adaptor protein critical in innate immune signaling and mitochondrial homeostasis. Initially identified as a mediator in Toll-like receptor (TLR) pathways, ECSIT interacts with TRAF6 and facilitates the activation of NF-κB and MAPK signaling, promoting pro-inflammatory cytokine production during microbial infection. Beyond immune regulation, ECSIT is integral to mitochondrial respiratory chain assembly by associating with complex I (NADH:ubiquinone oxidoreductase) subunits, linking cellular energy metabolism to immune responses. Its role in reactive oxygen species (ROS) generation further underscores its dual functionality in both host defense and oxidative stress modulation.
Recombinant ECSIT proteins are engineered using expression systems (e.g., *E. coli*, mammalian cells) to produce purified, functional ECSIT for mechanistic studies. These proteins retain key domains, including the N-terminal mitochondrial targeting sequence and C-terminal TRAF6-binding region, enabling researchers to dissect structure-function relationships. Recombinant ECSIT is widely used to study TLR signaling cascades, mitochondrial dysfunction in diseases (e.g., neurodegenerative disorders, cancer), and host-pathogen interactions. It also serves as a tool for identifying binding partners or screening therapeutic agents targeting inflammatory or metabolic pathways. By leveraging recombinant ECSIT, studies have revealed its phosphorylation-dependent regulation and pathological mutations affecting immune-metabolic crosstalk, highlighting its potential as a biomarker or therapeutic target.
×
